GraniteShares 2x Long COIN Daily ETF vs Immunovant Inc. Common Stock — how do they compare? GraniteShares 2x Long COIN Daily ETF trades at $5.09 (market cap $510.01M), while Immunovant Inc. Common Stock trades at $30.27 (market cap $6.25B). The key difference: Immunovant Inc. Common Stock is far larger — about 12.3× GraniteShares 2x Long COIN Daily ETF's market cap, and Immunovant Inc. Common Stock is trading nearer its 52-week high, GraniteShares 2x Long COIN Daily ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GraniteShares 2x Long COIN Daily ETF for 15 Days and Immunovant Inc. Common Stock for 0 Days on average.
| CONL | IMVT | |
|---|---|---|
Market Cap | $510.01M | $6.25B |
Volume | 21,041,836 | 1,755,411 |
Sector | Leveraged / Inverse | Health |
52-Week High | $48.58 | $44.96 |
52-Week Low | $3.93 | $17.03 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | — | $5.35B |
Signals from Pluang's Aura AI — not financial advice
CONL (GraniteShares 2x Long COIN Daily ETF) trades at $4.91, down 6.12% with bearish technical signals from moving averages. The ETF tracks Coinbase stock with 2x daily leverage, amplifying volatility. Recent news highlights significant price gaps and performance swings, with one article noting an 85% decline when Coinbase fell 50%. Technical indicators show oversold conditions with RSI readings below 30, suggesting potential near-term bounce.
Outlook remains highly speculative due to leveraged structure and dependency on Coinbase performance. Investment opportunity exists for tactical traders betting on Coinbase recovery, but risks include amplified losses, daily rebalancing decay, and crypto market volatility. Conservative investors should avoid due to extreme risk profile.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.
Read more on CONL →Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →